Does Chemically Modified Curcumin Control the Progression of Periodontitis? A Systematic Review

Area of Science:

• Periodontology
• Pharmacology
• Biochemistry

Background:

• Periodontitis involves connective tissue destruction driven by inflammatory diseases.
• Matrix metalloproteinase inhibitors (MMP-I) are explored for treating periodontitis.
• Chemically modified curcumin (CMC 2.24) offers improved solubility and bioavailability over curcumin for therapeutic use.

Purpose of the Study:

• To systematically review and analyze preclinical animal studies on the efficacy of CMC 2.24 in periodontitis.
• To assess the impact of CMC 2.24 on key indicators of periodontal disease progression in animal models.

Main Methods:

• Systematic review of English preclinical studies up to 2020.
• Inclusion of only randomized controlled trials (RCTs) investigating CMC 2.24 in induced periodontitis.
• Literature search conducted across PubMed, ScienceDirect, and Google Scholar.

Main Results:

• Seven trials involving 162 rats and 8 dogs were analyzed.
• Studies covered LPS-induced, diabetes-associated, and naturally occurring periodontitis models.
• Consistent findings showed CMC 2.24 significantly reduced alveolar bone loss and inhibited MMP activity.

Conclusions:

• CMC 2.24 demonstrates significant potential in preventing and treating periodontitis.
• The compound effectively inhibits matrix metalloproteinase activity, crucial in connective tissue destruction.
• CMC 2.24 shows promise as a therapeutic agent for mitigating bone loss in periodontitis.